Sakar Healthcare Ltd
Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]
- Market Cap ₹ 623 Cr.
- Current Price ₹ 286
- High / Low ₹ 479 / 280
- Stock P/E 50.2
- Book Value ₹ 124
- Dividend Yield 0.00 %
- ROCE 7.37 %
- ROE 5.34 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.23% over last 3 years.
- Company might be capitalizing the interest cost
- Promoter holding has decreased over last 3 years: -14.4%
- Working capital days have increased from 31.4 days to 62.0 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
22 | 30 | 35 | 41 | 44 | 53 | 68 | 83 | 95 | 128 | 133 | 153 | 164 | |
14 | 22 | 27 | 33 | 34 | 40 | 51 | 63 | 72 | 99 | 100 | 115 | 122 | |
Operating Profit | 8 | 8 | 8 | 8 | 10 | 13 | 17 | 20 | 23 | 29 | 33 | 38 | 42 |
OPM % | 34% | 26% | 22% | 20% | 23% | 24% | 25% | 24% | 24% | 23% | 25% | 25% | 26% |
0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 2 | 5 | 3 | 2 | |
Interest | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 6 | 8 | 7 |
Depreciation | 2 | 2 | 2 | 3 | 3 | 4 | 6 | 7 | 8 | 10 | 15 | 18 | 19 |
Profit before tax | 2 | 2 | 2 | 3 | 5 | 6 | 9 | 12 | 13 | 19 | 17 | 16 | 18 |
Tax % | 19% | 13% | 24% | 22% | 30% | 38% | 28% | 21% | 19% | 20% | 24% | 27% | |
1 | 2 | 2 | 2 | 3 | 4 | 7 | 10 | 11 | 15 | 13 | 12 | 12 | |
EPS in Rs | 1.81 | 2.19 | 2.30 | 2.78 | 3.08 | 3.12 | 4.47 | 6.43 | 6.84 | 8.90 | 6.70 | 5.37 | 5.70 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 18% |
5 Years: | 18% |
3 Years: | 17% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | 21% |
5 Years: | 11% |
3 Years: | 2% |
TTM: | -14% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 41% |
3 Years: | 25% |
1 Year: | -27% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 9% |
3 Years: | 8% |
Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 11 | 12 | 15 | 15 | 16 | 17 | 19 | 22 | 22 |
Reserves | 4 | 6 | 7 | 11 | 25 | 35 | 57 | 66 | 83 | 110 | 154 | 236 | 248 |
27 | 24 | 25 | 22 | 24 | 11 | 11 | 17 | 43 | 93 | 119 | 79 | 74 | |
11 | 14 | 11 | 10 | 11 | 23 | 15 | 17 | 37 | 47 | 44 | 52 | 61 | |
Total Liabilities | 50 | 52 | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 404 |
37 | 38 | 36 | 37 | 49 | 53 | 64 | 66 | 69 | 205 | 267 | 314 | 317 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 13 | 49 | 1 | 6 | 0 | 1 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 3 | 0 | 0 |
13 | 14 | 14 | 14 | 22 | 28 | 25 | 36 | 60 | 55 | 60 | 74 | 87 | |
Total Assets | 50 | 52 | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 404 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | 9 | 4 | 9 | 2 | 5 | 16 | 19 | 15 | 36 | 33 | 24 | |
-3 | -3 | -1 | -4 | -14 | -8 | -25 | -22 | -47 | -90 | -74 | -52 | |
-7 | -6 | -3 | -6 | 13 | -13 | 9 | 3 | 32 | 55 | 41 | 27 | |
Net Cash Flow | -4 | -0 | 1 | -1 | 0 | -16 | 0 | -0 | -0 | -0 | 0 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 22 | 28 | 21 | 26 | 44 | 74 | 51 | 36 | 48 | 40 | 60 | 50 |
Inventory Days | 281 | 190 | 142 | 107 | 114 | 51 | 70 | 92 | 112 | 69 | 76 | 121 |
Days Payable | 109 | 97 | 20 | 66 | 51 | 57 | 41 | 46 | 141 | 149 | 129 | 120 |
Cash Conversion Cycle | 194 | 120 | 143 | 67 | 107 | 68 | 80 | 83 | 19 | -39 | 7 | 51 |
Working Capital Days | 155 | 75 | 89 | 45 | 110 | 108 | 46 | 41 | 8 | 2 | 30 | 62 |
ROCE % | 14% | 15% | 14% | 14% | 15% | 15% | 16% | 16% | 13% | 12% | 9% | 7% |
Documents
Announcements
-
Updates
23 October 2024 - Sakar Healthcare Limited has informed regarding 'Clarification on outcome of Board meeting Submitted on 22-10-2024.'.
-
Outcome of Board Meeting
22 October 2024 - Sakar Healthcare Limited has informed regarding Board meeting held on October 22, 2024.
-
Financial Result Updates
22 October 2024 - Sakar Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024.
-
Board Meeting Intimation
17 October 2024 - SAKAR HEALTHCARE LIMITED has informed about Board Meeting to be held on 22-Oct-2024 to inter-alia consider and approve the Unaudited Financial results of the Company …
-
General Updates
10 October 2024 - Sakar Healthcare Limited has informed about submission of Certificate under Regulation 74 (5) of the SEBI (Depositories and Participants)Regulations, 2018 for the Quarter Ended 30th …
Annual reports
Concalls
-
Oct 2022TranscriptNotesPPT
Business Overview:[1][2][3]
SHL, certified by ISO 9001:2015 (BVQI), WHO-GMP, cGMP, and the National Drug Authority, provides comprehensive healthcare and pharmaceutical products. Operating in over 50 countries with 292 registered products and 210 more under registration, SHL partners with 70+ overseas distributors. The company also engages in contract manufacturing for leading domestic brands and direct sales in both domestic and export markets.